MAIA Biotechnology, Inc. Cash and Restricted Cash
MAIA Biotechnology, Inc. (MAIA) had Cash and Restricted Cash of $10.86 million as of 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2025-05-09
- 2025-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.86M.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.60M.
- 2024-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.69M.
- 2024-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.58M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2025-03-31 | $10.86M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $9.60M 10-Q · filed 2025-05-09 |
| 2024-09-30 | $8.69M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.58M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $8.27M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $7.15M 10-Q · filed 2025-05-09 |
| 2023-09-30 | $6.10M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $9.15M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $7.59M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $10.95M 10-K · filed 2025-03-21 |
| 2022-09-30 | $14.06M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $8.15M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $10.29M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $10.57M 10-K · filed 2024-03-21 |
| 2021-09-30 | $10.95M 10-Q/A · filed 2023-02-06 |
| 2021-06-30 | $6.78M 10-Q · filed 2022-08-22 |
| 2020-12-31 | $663.46K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |